Colon cancer: Cancer stem cells markers, drug resistance and treatment

Biomedicine and Pharmacotherapy

Volumn 68, Issue 8, 2014, Pages 911-916

  Kozovska, Zuzana ^a   Gabrisova, Veronika ^b   Kucerova, Lucia ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b Department of Pharmaceutical Analysis and Nuclear Pharmacy   (Slovakia)

Author keywords

Aldehyd dehydrogenase ALDH1; Cancer stem cells markers; Colon cancer; Multidrug resistance

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; PHYSIOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASTIC STEM CELLS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84916230380     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.10.019     Document Type: Review

References (84)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Marin J.J., Monte M.J., Blazquez A.G., Macias R.I., Serrano M.A., Briz O. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. Acta Pharmacol Sin 2014, 35:1-10.
3. Recondo G.J., Diaz-Canton E., de la Vega M., Greco M., Recondo G.S., Valsecchi M.E. Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol 2014, 6:211-224.
4. Hong W.K., Research A.A.f.C., Hait W. Holland Frei Cancer Medicine Eight 2010, People's Medical Publishing House.
5. Dutour A., Leclers D., Monteil J., Paraf F., Charissoux J.L., Rousseau R., et al. Non-invasive imaging correlates with histological and molecular characteristics of an osteosarcoma model: application for early detection and follow-up of MDR phenotype. Anticancer Res 2007, 27:4171-4178.
6. Langley R.R., Fidler I.J. The biology of brain metastasis. Clin Chem 2013, 59:180-189.
7. La Porta C.A. Drug resistance in melanoma: new perspectives. Curr Med Chem 2007, 14:387-391.
8. Matuskova M., Baranovicova L., Kozovska Z., Durinikova E., Pastorakova A., Hunakova L., et al. Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells. J Gene Med 2012, 14:776-787.
9. Altanerova V., Cihova M., Babic M., Rychly B., Ondicova K., Mravec B., et al. Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase: uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma. Int J Cancer 2012, 130:2455-2463.
10. Kucerova L., Poturnajova M., Tyciakova S., Matuskova M. Increased proliferation and chemosensitivity of human mesenchymal stromal cells expressing fusion yeast cytosine deaminase. Stem Cell Res 2012, 8:247-258.
11. Matuskova M., Hlubinova K., Pastorakova A., Hunakova L., Altanerova V., Altaner C., et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett 2010, 290:58-67.
12. Durinikova E., Kucerova L., Matuskova M. Mesenchymal stromal cells retrovirally transduced with prodrug-converting genes are suitable vehicles for cancer gene therapy. Acta Virol 2014, 58:1-13.
13. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
14. Poste G., Fidler I.J. The pathogenesis of cancer metastasis. Nature 1980, 283:139-146.
15. Heng H.H., Stevens J.B., Liu G., Bremer S.W., Ye K.J., Reddy P.V., et al. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol 2006, 208:461-472.
16. Grady W.M., Markowitz S. Genomic instability and colorectal cancer. Curr Opin Gastroenterol 2000, 16:62-67.
17. Diaz-Cano S.J. Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci 2012, 13:1951-2011.
18. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007, 104:10158-10163.
19. Heppner G.H. Tumor heterogeneity. Cancer Res 1984, 44:2259-2265.
20. Lobo N.A., Shimono Y., Qian D., Clarke M.F. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007, 23:675-699.
21. Ward R.J., Dirks P.B. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2007, 2:175-189.
22. Cho R.W., Clarke M.F. Recent advances in cancer stem cells. Curr Opin Genet Dev 2008, 18:48-53.
23. Morrison S.J., Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006, 441:1068-1074.
24. Morrison S.J., Qian D., Jerabek L., Thiel B.A., Park I.K., Ford P.S., et al. A genetic determinant that specifically regulates the frequency of hematopoietic stem cells. J Immunol 2002, 168:635-642.
25. Moitra K., Lou H., Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 2011, 89:491-502.
26. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
27. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
28. Huang E.H., Hynes M.J., Zhang T., Ginestier C., Dontu G., Appelman H., et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69:3382-3389.
29. Ke J., Wu X., He X., Lian L., Zou Y., Wang H., et al. A subpopulation of CD24(+) cells in colon cancer cell lines possess stem cell characteristics. Neoplasma 2012, 59:282-288.
30. Wilson B.J., Schatton T., Frank M.H., Frank N.Y. Colorectal Cancer Stem Cells: Biology and Therapeutic Implications. Curr Colorectal Cancer Rep 2011, 7:128-135.
31. Vermeulen L., Todaro M., de Sousa Mello F., Sprick M.R., Kemper K., Perez Alea M., et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 2008, 105:13427-13432.
32. Ong C.W., Kim L.G., Kong H.H., Low L.Y., Iacopetta B., Soong R., et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 2010, 23:450-457.
33. Du L., Wang H., He L., Zhang J., Ni B., Wang X., et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008, 14:6751-6760.
34. Vasiliou V., Nebert D.W. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics 2005, 2:138-143.
35. Landen C.N., Goodman B., Katre A.A., Steg A.D., Nick A.M., Stone R.L., et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010, 9:3186-3199.
36. Ma I., Allan A.L. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 2011, 7:292-306.
37. Koppaka V., Thompson D.C., Chen Y., Ellermann M., Nicolaou K.C., Juvonen R.O., et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application, Pharmacol Rev 2012, 64:520-539.
38. Su Y., Qiu Q., Zhang X., Jiang Z., Leng Q., Liu Z., et al. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 2010, 19:327-337.
39. Kim M.P., Fleming J.B., Wang H., Abbruzzese J.L., Choi W., Kopetz S., et al. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS ONE 2011, 6:e20636.
40. Honoki K., Fujii H., Kubo A., Kido A., Mori T., Tanaka Y., et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 2010, 24:501-505.
41. Croker A.K., Allan A.L. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44(+) human breast cancer cells. Breast Cancer Res Treat 2012, 133:75-87.
42. Kang E.J., Jung H., Woo O.H., Park K.H., Woo S.U., Yang D.S., et al. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer. Neoplasma 2014, 61:352-362.
43. Zhang M., Shoeb M., Goswamy J., Liu P., Xiao T.L., Hogan D., et al. Overexpression of aldehyde dehydrogenase 1A1 reduces oxidation-induced toxicity in SH-SY5Y neuroblastoma cells. J Neurosci Res 2010, 88:686-694.
44. Lawenda B.D., Kelly K.M., Ladas E.J., Sagar S.M., Vickers A., Blumberg J.B. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?. J Natl Cancer Inst 2008, 100:773-783.
45. Donnenberg V.S., Donnenberg A.D. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005, 45:872-877.
46. Zeimet A.G., Reimer D., Sopper S., Boesch M., Martowicz A., Roessler J., et al. Ovarian cancer stem cells. Neoplasma 2012, 59:747-755.
47. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts. Annu Rev Med 2007, 58:267-284.
48. Popek S., Tsikitis V.L. Neoadjuvant vs adjuvant pelvic radiotherapy for locally advanced rectal cancer: Which is superior?. World J Gastroenterol 2011, 17:848-854.
49. Benson A.B., Schrag D., Somerfield M.R., Cohen A.M., Figueredo A.T., Flynn P.J., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408-3419.
50. Wohlhueter R.M., McIvor R.S., Plagemann P.G. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 1980, 104:309-319.
51. Matherly L.H., Czajkowski C.A., Muench S.P., Psiakis J.T. Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2'-deoxyuridine antitumor activity in vitro. Cancer Res 1990, 50:3262-3269.
52. Park J.G., Collins J.M., Gazdar A.F., Allegra C.J., Steinberg S.M., Greene R.F., et al. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst 1988, 80:1560-1564.
53. Nadal J.C., Van Groeningen C.J., Pinedo H.M., Peters G.J. In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed Pharmacother 1988, 42:387-393.
54. Wright J.E., Dreyfuss A., el-Magharbel I., Trites D., Jones S.M., Holden S.A., et al. Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res 1989, 49:2592-2596.
55. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998, 34:1274-1281.
56. Cao D., Russell R.L., Zhang D., Leffert J.J., Pizzorno G. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 2002, 62:2313-2317.
57. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
58. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260:14873-14878.
59. Woynarowski J.M., Chapman W.G., Napier C., Herzig M.C., Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998, 54:770-777.
60. Segal N.H., Saltz L.B. Evolving treatment of advanced colon cancer. Annu Rev Med 2009, 60:207-219.
61. Eastman A. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). Biochemistry 1983, 22:3927-3933.
62. Chaney S.G., Campbell S.L., Bassett E., Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005, 53:3-11.
63. Zdraveski Z.Z., Mello J.A., Farinelli C.K., Essigmann J.M., Marinus M.G. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J Biol Chem 2002, 277:1255-1260.
64. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4:307-320.
65. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
66. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987, 34:155-166.
67. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
68. Shen D., Pastan I., Gottesman M.M. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 1998, 58:268-275.
69. Kelland L.R. Preclinical perspectives on platinum resistance. Drugs 2000, 59(Suppl. 4):1-8. [discussion 37-38].
70. Shen D.W., Goldenberg S., Pastan I., Gottesman M.M. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 2000, 183:108-116.
71. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
72. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.
73. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001, 15:719-730.
74. Synold T.W., Dussault I., Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001, 7:584-590.
75. Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001, 11:1156-1166.
76. Polgar O., Bates S.E. ABC transporters in the balance: is there a role in multidrug resistance?. Biochem Soc Trans 2005, 33:241-245.
77. Steinbach D., Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?. Leukemia 2007, 21:1172-1176.
78. Ford J.M., Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990, 42:155-199.
79. Glavinas H., Krajcsi P., Cserepes J., Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004, 1:27-42.
80. Ye P., Zhang W., Yang T., Lu Y., Lu M., Gai Y., et al. Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. Int J Nanomedicine 2014, 9:2167-2178.
81. Huang L., Li F., Sheng J., Xia X., Ma J., Zhan M., et al. DrugComboRanker: drug combination discovery based on target network analysis. Bioinformatics 2014, 30:i228-i236.
82. Cihova M., Altanerova V., Altaner C. Stem cell based cancer gene therapy. Mol Pharm 2011, 8:1480-1487.
83. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
84. Kucerova L., Feketeova L., Kozovska Z., Poturnajova M., Matuskova M., Nencka R., et al. In vivo 5FU-exposed human medullary thyroid carcinoma cells contain a chemoresistant CD133+ tumor-initiating cell subset. Thyroid 2014, 24:520-532.